Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-13Clinical Trial Update: A Novel Haemostatic Agent for Robotic Partial Nephrectomy [NA]
A clinical trial evaluating a novel haemostatic agent for robotic partial nephrectomy has been withdrawn from ClinicalTrials.gov.
-
CLINICAL_TRIALS withdrawal · 2026-02-17Clinical Trial Update: Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) [Phase 2]
A Phase 2 trial evaluating acarbose in combination with standard therapy for metastatic renal cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-12-24Clinical Trial Update: STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma [Phase 1]
A Phase 1 study of STIL101 for injection across pancreatic ductal adenocarcinoma, colorectal cancer, renal cell carcinoma, cervical cancer, …
-
CLINICAL_TRIALS withdrawal · 2025-12-19Clinical Trial Update: Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) [NA]
A clinical trial investigating time-restricted eating in metastatic head and neck squamous cell carcinoma and unresectable or metastatic ren…
-
CLINICAL_TRIALS withdrawal · 2025-11-12Clinical Trial Update: A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma [Phase 1, Phase 2]
This clinical trial update reports the termination of a Phase 1/2 study of NKT2152, a HIF2α inhibitor, in patients with advanced clear cell …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-08-19Clinical Trial Update: PSMA Therapy and Immunotherapy in Kidney Cancer [Phase 1, Phase 2]
A clinical trial investigating PSMA-targeted therapy and immunotherapy for metastatic renal cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-08-13Clinical Trial Update: Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases [Phase 2]
This Phase 2 trial of lenvatinib plus pembrolizumab in immune-refractory metastatic renal cell carcinoma with brain metastases has been with…
-
CLINICAL_TRIALS withdrawal · 2025-06-26Clinical Trial Update: iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
The iConquerFear program for Fear of Cancer Recurrence in patients with localized renal cell carcinoma has been withdrawn from the clinical …
-
CLINICAL_TRIALS withdrawal · 2025-05-02Clinical Trial Update: Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery [EARLY_Phase 1]
A clinical trial evaluating contrast-enhanced ultrasound to predict treatment response in renal cell carcinoma patients undergoing cryosurge…
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona [NA]
This clinical trial evaluating a social support intervention for Hispanic patients with renal cell carcinoma or hepatocellular carcinoma in …
-
CLINICAL_TRIALS withdrawal · 2024-10-26Clinical Trial Update: MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial [Phase 2]
Phase 2 trial MRI-MARK evaluating MRI-guided radiation therapy for early-stage renal cell carcinoma has been withdrawn.
-
EMA withdrawal · 2024-10-24EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. …
-
CLINICAL_TRIALS withdrawal · 2024-08-02Clinical Trial Update: Impact of Perioperative Anesthetic Management on Renal Cancer Progression.
The clinical trial investigating the impact of perioperative anesthetic management on renal cancer progression has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-04-26Clinical Trial Update: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer [Phase 2]
A Phase 2 trial of cabozantinib before cytoreductive nephrectomy in advanced or metastatic renal cell carcinoma was terminated.
-
CLINICAL_TRIALS withdrawal · 2024-04-26Clinical Trial Update: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary [Phase 1]
A Phase 1 trial evaluating nivolumab plus ipilimumab with immunostimulatory embolization for stage IV renal cell carcinoma with an unresecte…
-
CLINICAL_TRIALS withdrawal · 2018-11-15Clinical Trial Update: A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma [Phase 3]
A Phase 3 trial evaluating atezolizumab with bevacizumab in untreated locally advanced or metastatic renal cell carcinoma has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2018-07-02Clinical Trial Update: Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) [Phase 1, Phase 2]
The NivoPlus trial evaluating nivolumab plus chemotherapy in various advanced cancers has been terminated (Phase 1/Phase 2).
-
CLINICAL_TRIALS withdrawal · 2018-06-18Clinical Trial Update: Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab [Phase 2]
An investigator-initiated Phase 2 trial evaluating the combination of ipilimumab, nivolumab, and stereotactic radiation for metastatic clear…
-
CLINICAL_TRIALS withdrawal · 2018-06-14Clinical Trial Update: Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma [Phase 3]
A Phase 3 trial of autologous dendritic cell immunotherapy plus standard treatment for advanced/metastatic renal cell carcinoma was terminat…
-
CLINICAL_TRIALS withdrawal · 2018-03-05Clinical Trial Update: Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) [Phase 2]
Phase 2 trial of combining radiation with PD-1 inhibition in metastatic or recurrent renal cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-12-22Clinical Trial Update: REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT [Phase 3]
Phase 3 trial REDECT 2 for detecting clear cell renal cell carcinoma with PET/CT has been withdrawn.
-
EMA withdrawal · 2017-11-10EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.
The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.
-
CLINICAL_TRIALS withdrawal · 2017-07-17Clinical Trial Update: Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
A clinical trial evaluating healthcare costs and resource utilization for metastatic renal cell carcinoma treatments using intravenous and o…